Drug intelligence / Profile preview

Woulgan

Development stage
Unknown
Lead developer
Biotec BetaGlucans
Modality
Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

Woulgan is a bioactive wound-healing hydrogel containing 2% soluble beta-1,3/1,6-glucan (SBG) extracted from Saccharomyces cerevisiae and formulated in a high-water hydrogel base to treat stalled or slow-healing acute and chronic wounds. The SBG component acts as an immunomodulator that activates macrophages and other innate immune cells, promoting a controlled inflammatory response, angiogenesis, fibroblast proliferation, granulation tissue formation, and wound contraction, while the hydrogel matrix maintains a moist environment, rehydrates necrotic tissue, and supports autolytic debridement. Woulgan is indicated for dry to medium-exuding partial- or full-thickness wounds, including diabetic foot ulcers, leg ulcers of any aetiology, pressure ulcers, graft and donor sites, open surgical wounds, partial-thickness burns, abrasions, and lacerations, particularly where healing is delayed or at high risk of becoming stalled, and is used as an adjunct to standard wound care under healthcare professional supervision.

Brand names
Woulgan
Other names
Woulgan Bioactive Beta-Glucan GelWoulgan BiogelWoulgan Bioactive Beta-Glucan
02

Targets

CLEC7A (Dectin-1)

Beyond the preview

Go deeper on Woulgan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Woulgan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call